Jiangsu Alphamab Oncology

Alphamab Oncology is a leading clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative biologics for oncology. The company leverages its proprietary protein engineering platforms, such as CRIB and CRAM, to create a diverse pipeline of multi-functional antibody-based therapies, including bispecific antibodies and antibody-drug conjugates. Its lead product, Envafolimab, is the world's first subcutaneous PD-L1 inhibitor approved for the treatment of microsatellite instability-high (MSI-H) solid tumors. Alphamab maintains a robust clinical pipeline with several candidates in late-stage development targeting high-prevalence cancers like gastric, breast, and lung cancer. The company is committed to providing differentiated and affordable next-generation immunotherapy solutions to patients globally.